Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

8.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

12
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
12

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.

The American journal of clinical nutrition·2026
Same author

Unintended consequences of legacy oversight in digital medicine.

Nature medicine·2026
Same author

Feasibility and acceptability of an electronic decision aid for genetic testing in ovarian and pancreatic cancer patients.

Research connections·2026
Same author

The Ethics of Liver Transplant for Colorectal Metastases.

JAMA surgery·2026
Same author

Prostate Cancer Risk and DNA Mismatch Repair Deficiency Among Lynch Syndrome Patients.

European urology open science·2025
Same author

Gastric Polyposis and Cancer in Western Patients With Familial Adenomatous Polyposis: Epidemiology, Detection, and Management.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Related Experiment Video

Updated: Feb 17, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

937

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.

Samir Gupta, Dawn Provenzale, Scott E Regenbogen

    Journal of the National Comprehensive Cancer Network : JNCCN
    |December 11, 2017
    PubMed
    Summary

    The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal offer updated management strategies for colorectal cancer (CRC) risk. They incorporate new genes linked to CRC on multigene panels and the latest evidence for high-risk patients.

    More Related Videos

    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
    07:35

    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

    Published on: June 8, 2020

    7.5K
    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.8K

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    937
    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
    07:35

    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

    Published on: June 8, 2020

    7.5K
    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.8K

    Area of Science:

    • Oncology
    • Genetics
    • Cancer Research

    Background:

    • Colorectal cancer (CRC) poses a significant health risk, with genetic and familial factors playing a crucial role.
    • High-risk syndromes necessitate specialized management strategies to mitigate CRC development.
    • The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for cancer care.

    Purpose of the Study:

    • To update recommendations for the management of patients with high-risk syndromes associated with colorectal cancer (CRC).
    • To incorporate newly identified genes associated with CRC risk identified through multigene panels.
    • To present the latest evidence and management strategies for genetic/familial high-risk assessment in CRC.

    Main Methods:

    • The NCCN Panel for Genetic/Familial High-Risk Assessment: Colorectal convenes annually to review data and comments.
    • The panel evaluates newly identified genes associated with CRC risk on multigene panels.
    • Evidence supporting gene associations and management strategies is critically examined.

    Main Results:

    • Identification of novel genes associated with an increased risk of colorectal cancer (CRC).
    • Assessment of the clinical evidence linking these genes to CRC predisposition.
    • Development of updated management strategies based on the latest genetic findings and evidence.

    Conclusions:

    • The NCCN Guidelines provide essential, updated recommendations for managing hereditary colorectal cancer.
    • Incorporating new genetic discoveries into risk assessment improves patient care for individuals at high risk of CRC.
    • Regular guideline updates ensure that management strategies align with the evolving scientific landscape in cancer genetics.